Nooshin Ghavidel - Social Determinants of Health Research Center, Alborz University of Medical Sciences, Karaj, Iran
Sareh Asadi - NeuroBiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Jamal Shams - Behavioral Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran
Fariba Khodagholi - Neuroscience Research Center, ShahidBeheshti University of Medical Sciences, Tehran, Iran
Abolhassan Ahmadiani - Neuroscience Research Center, ShahidBeheshti University of Medical Sciences, Tehran, Iran

Background and Aim : Although it has been reported that methamphetamine (MA) induces brain dysfunction, increases levels of oxidative stress and psychiatric symptoms, no study has been conducted to study their correlation in MA-dependent patients. The aim of this study was evaluating the correlation of serum levels of PON1 (an antioxidant), and depression and anxiety state of MA-dependent patient.Methods : Nineteen active MA abusers and 18 control subjects were included in the study. Socio-demographic and Addiction Severity Index (ASI) questionnaires were used to determine medical, drug use and family/social status. Depression, anxiety and stress scale - 21 Items (DASS-21) questionnaire was used for evaluation of their depression, anxiety, and stress. Their blood samples were collected to measure the level of PON1 by the human enzyme-linked immunosorbent assay (ELISA) kit. The data were analyzed using Graph Pad PRISM software.Results : Results showed significantly lower levels of serum PON1and higher levels of depression/anxiety in MA abusers compared to the controls. Data analysis revealed a negative correlation between PON1 level and depression/anxiety state in studied subjects.Conclusion : Our results showed higher levels of depression/anxiety which was associated with lower levels of serum PON1 in the MA-dependent patients. Further studies need to elucidate their roles in the pathophysiology of MA addiction.

Anxiety, Depression, Methamphetamine, PON1, Antioxidant